Long-term survival case of a non-small cell lung cancer bone metastasis patient treated with bone cement, radiation and gefitinib

CONCLUSIONS: The median survival time for NSCLC patients with bone metastases is often less than 1 year. We reported the patient with more than eight years of survival, showed that some special cases can adopt the methods of local treatment including bone cement, treatment benefit patients, radiation therapy and targeted therapy in clinic to expand the survival.PMID:33829440 | DOI:10.26355/eurrev_202103_25417

Source: European Review for Medical and Pharmacological Sciences - April 8, 2021 Category: Drugs & Pharmacology Authors: W-T Hou X-Q Xie Y Luo C Yi F Luo J-B Kang F Wang Y Lu Y-L Gong D-B Wu B-L Qu Source Type: research